Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 172

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Microbiologic Outcome of Interventions Against Mycobacterium avium Complex Pulmonary Disease

Diel, Roland, Nienhaus, Albert, Ringshausen, Felix C., Richter, Elvira, Welte, Tobias, Rabe, Klaus F., Loddenkemper, Robert·2018·Chest

Abstract

OBJECTIVE: Pulmonary disease (PD) caused by Mycobacterium avium complex (MAC) is increasing worldwide. We conducted a systematic review of studies that include microbiologic outcomes to evaluate current macrolide‐based treatment regimens. METHODS: We searched literature published before April 2017 by using the MEDLINE, Cochrane, and Embase databases. Risk of bias in randomized trials was assessed using the Cochrane tool. RESULTS: We retrieved 333 citations and evaluated 42 studies including 2,748 patients: 18 studies were retrospective chart reviews, 18 were prospective, and six were randomized. The weighted average proportion of sputum culture conversions in macrolide‐containing regimens after subtracting posttreatment microbiologic recurrences was 52.3% (95% CI, 44.7%‐59.9%). Using the triple‐drug regimens recommended by the American Thoracic Society (ATS) achieved treatment success in 61.4% (95% CI, 49.7%‐72.5%), which further increased to 65.7% (95% CI, 53.3%‐77.4%) when drugs were taken for at least 1 year by patients who were macrolide susceptible and had previously untreated MAC. The overall risk of bias was low in five of the six randomized trials. However, selective outcome reporting because of a posteriori exclusion of initially included patients (14.0%), uncompleted treatment (17.6%), and inconsistent use of outcome parameters (17 definitions of treatment success) hampered the comparison of nonrandomized trials. CONCLUSIONS: To date, randomized studies on treatment outcome in patients with MAC PD are scarce. Long‐term treatments with ATS‐recommended regimens for patients who are macrolide susceptible are superior to other macrolide‐based therapies. A standardized definition of treatment success and genotypic distinction between reinfection and relapse by means of pretreatment and posttreatment identification of MAC species in cases of microbiologic recurrences may help to optimize evaluation of treatment regimens in the future.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.chest.2018.01.024

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 172

Metadata

Authors
Diel, R., Nienhaus, A., Ringshausen, F. C., Richter, E., Welte, T., Rabe, K. F., & Loddenkemper, R.
Venue
Chest
Publisher
Elsevier BV
Published
2018-04
Volume
153
Issue
4
Pages
888-921
ISSN
0012-3692 (ISSN-L)
OpenAlex
W2787709298
Cited by
172
References
1
FWCI
9.72
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Microbiologic Outcome of Interventions Against Mycobacterium avium Complex Pulmonary Disease. https://app.cochat.ai/papers/10.1016/j.chest.2018.01.024
The paper
Diel, R., Nienhaus, A., Ringshausen, F. C., Richter, E., Welte, T., Rabe, K. F., & Loddenkemper, R. (2018). Microbiologic Outcome of Interventions Against Mycobacterium avium Complex Pulmonary Disease. Chest. https://doi.org/10.1016/j.chest.2018.01.024

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.